AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04338256 — intervention group
Intervention type: BEHAVIORAL
Intervention: Wellness and Resilience for College and Beyond (Undergraduate College Course)
Description: The course, Wellness and Resilience for College and Beyond was originally developed by James Mazza, PhD and colleagues at the University of Washington as a 10-week course. The course developers adapted their course materials to fit the needs of a 16-week semester for the purpose of this study. The Wellness Course teaches students evidence-based skills for improving mental health from dialectical behavior therapy, acceptance and commitment therapy, and the field of positive psychology. Classes meet for 2.5 hours weekly with approximately half of class time spent on teaching new content (lecture) and the other half spent with students working in small groups on practice and discussion exercises.
Study NCT05087576 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive Helping
Description: Expressive helping integrates two distinct areas of research showing that emotional disclosure over writing and support giving improves psychological well-being among healthy and clinical populations. Participants write 4 brief structured writing sessions.
Study NCT05087576 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caregiving Fact writing
Description: Factual Writing has been used with in other writing-based interventions (e.g., expressive writing). It is also completed in 4 brief structured writing sessions.
Study NCT03246321 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: repetitive ePIPAC-OX
Description: Instead of standard palliative treatment, enrolled patients receive laparoscopy-controlled electrostatic pressurised intraperitoneal aerosol chemotherapy with oxaliplatin (ePIPAC-OX) (92 mg/m2 body-surface area \[BSA\]) with intravenous leucovorin (20 mg/m2 BSA) and bolus 5-fluorouracil (400 mg/m2 BSA) every six weeks. Four weeks after each procedure, patients undergo clinical, radiological, and biochemical evaluation. ePIPAC-OX is repeated until clinical, radiological, or macroscopic disease progression, after which standard palliative treatment is (re)considered.
Study NCT01155258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV
Study NCT01155258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine ditartrate
Description: Given IV
Study NCT02934568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: Single agent LEE011 or in combination with other treatments
Study NCT03992612 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: control group: usual medical care
Description: The patients received usual medical care.
Study NCT03992612 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBPM- Mindfulness-Based Pain Management
Description: 8 group session of maindfulness-based treatment to management pain
Study NCT03647280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Tailored neoadjuvant chemotherapy with 4 cycles of PE(weekly Abraxane 125mg/m2, Q3week Epirubicin 100mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
Study NCT03647280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Tailored neoadjuvant chemotherapy with 4 cycles of PE(weekly Abraxane 125mg/m2, Q3week Epirubicin 100mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
Study NCT01923961 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HDF NaCl
Study NCT01923961 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemodialysis
Study NCT01923961 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Predilution Hemodiafiltration
Study NCT03187873 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chama cha MamaToto
Description: Chamas are a community-led model of peer support for women in pregnancy and infancy. Chamas are highly gendered institutions that women have relied on for survival to pool resources. Using this existing cultural script, chamas have been tailored to the needs of pregnant women. Central to the approach is the integration of health, social and financial literacy education with a savings/loans program. Chamas are designed to improve MNCH by generating positive peer support for women to advocate for themselves and account for the care they receive.
Study NCT03717298 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ocoxin-Viusid®
Description: An oral solution of Ocoxin-Viusid® (30 ml vials) will be used at a rate of 60 ml daily (1 vial every 12 hours), preferably administered after breakfast and lunch. It will be prescribed for a period of 2 weeks before starting the QT.~The treatment with Ocoxin-Viusid® will continue in the possible periods of time of suspension of the chemotherapy treatment due to toxicities attributable to the oncospecific treatment.~The treatment will be administered continuously from the inclusion of the patient in the study, up to one year.
Study NCT02185027 — intervention group
Intervention type: OTHER
Intervention: complications and compliance with GIHP recommendations
Description: Description of complications, compliance, major bleeding events, treatments, reversal strategies.
Study NCT02572427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education for intubation skills
Description: Routine training in neonatal resuscitation, intensive cognitive and hands on training for intubating neonates using manikins in a simulation lab.
Study NCT02572427 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No added education for intubation skills
Description: Routine training in neonatal resuscitation but no added experience in simulation lab.
Study NCT04357769 — intervention group
Intervention type: OTHER
Intervention: PSS (Perceived Stress Scale)
Description: Self-administered scale for the evaluation of the stress perceived by the subject in the last weeks
Study NCT04357769 — intervention group
Intervention type: OTHER
Intervention: GAD-7 (7-item Generalized Anxiety Disorder)
Description: Self-administered scale for the evaluation of anxiety symptoms in the last weeks
Study NCT04357769 — intervention group
Intervention type: OTHER
Intervention: PHQ-9 (9-item Patient Health Questionnaire)
Description: Self-administered scale for the evaluation of depressive symptoms in the last weeks
Study NCT04232696 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuspera Implantable Sacral Nerve Stimulation System
Description: Stimulation of the Sacral Nerve.
Study NCT04074356 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical measure questionnaires
Description: Collection of patient reported symptoms and perception of health
Study NCT04357769 — intervention group
Intervention type: OTHER
Intervention: SPEQ (Specific Psychotic Experiences Questionnaire) - Paranoia and Grandiosity Subscales
Description: Self-administered scale for the evaluation of sub-threshold psychotic symptoms in the last weeks
Study NCT04357769 — intervention group
Intervention type: OTHER
Intervention: Zaritt Burden Interview
Description: Self-administered scale for the evaluation of severe mental disorder patients' caregiver burden
Study NCT03176069 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation and Comparison of women pelvic floor with and without sexual dysfunction
Description: Pelvic floor muscles will also be evaluated by electromyographic biofeedback.
Study NCT04074356 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: EESG
Description: Use of silver-silver chloride cutaneous electrogastrogram (EGG) electrodes to get myoelectrical readings
Study NCT04074356 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MESG
Description: MESG measures spatiotemporal properties of magnetic fields from the esophageal slow wave and allows characterization of the propagation of the slow wave in addition to evaluation of its frequency and power distribution
Study NCT04074356 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: High resolution manometry (HRM)
Description: Dysphagia subjects will have undergone standard of care HRM to determine placement in the achalasia or hypercontractile/spastic disorder arms
Study NCT00318409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Study NCT00318409 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03297801 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Fish oil supplements
Description: Women who chose to supplement with fish oil during gestation or lactation.
Study NCT02404272 — intervention group
Intervention type: OTHER
Intervention: Educational oral feeding nurse program
Description: A multidisciplinary group composed of childcare assistants, nurse guardians, speech therapist, physiotherapist, psychologist, and pediatricians will develop and implement the educational oral feeding program. They will provide the 2-day theoretical session as well as the three 2-hour practical sessions including reviews of video recording preterm neonates during bottle or breast feedings.~The program will focus on non-nutritive sucking for all neonates from 24 up to 34 weeks' of gestation, early oral feeding from 29 weeks' of gestation and oral stimulation for all preterm neonates admitted to the unit. Additionally, all preterm neonates presenting feeding difficulties symptoms will be evaluated weekly by a physiotherapist or speech therapist.~Each program session is composed of 20 nurses or childcare assistants. Six sessions will be organized in total and all nurses and childcare assistants will be trained
Study NCT01731431 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Study NCT01731431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyburide
Study NCT00527527 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: flexion distraction
Description: Chiropractic treatment using the flexion distraction apparatus
Study NCT00527527 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo control
Description: Placebo for comparison with flexion distraction treatment
Study NCT02179385 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coaching
Study NCT02091388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03004
Study NCT03503968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDG1011
Description: PRAME-T-Cell Receptor Gene Modified Autologous T Cells
Study NCT03503968 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Investigator Choice therapy
Description: Any intervention/therapy chosen by the investigator
Study NCT00165282 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Description: Taught mindfulness meditation by mindfulness instructor (trained health care professional/RN) and audio c/d
Study NCT02091388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperdal® Consta®
Study NCT00165282 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nurse education
Description: Meets with oncology nurse to have questions answered about medical treatments and side effects
Study NCT05706558 — intervention group
Intervention type: PROCEDURE
Intervention: Esophagectomy
Description: Esophagectomy
Study NCT01732666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nefopam
Description: 20 mg of Nefopam mixed in 100 ml of 0.9% saline IV immediately after induction of anesthesia.
Study NCT01732666 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: low dose remifentanil
Description: 100 ml of 0.9% saline immediately after anesthesia induction and 0.05µg/kg/min of remifentanil during anesthesia.
Study NCT01732666 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: high dose remifentanil
Description: 100 ml of 0.9% saline immediately after anesthesia induction and 0.3 µg/kg/min of remifentanil during anesthesia.
Study NCT00572468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: 40 mg of simvastatin
Study NCT00572468 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT01570998 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intraoperative Radiation Therapy
Description: Undergo IORT
Study NCT01570998 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03176069 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The physiotherapeutic treatment
Description: The available treatment tools are educational, behavioral and rehabilitating. The physiotherapeutic treatment will consist of the following features:~* Kinesiotherapy~* Manual therapy~* Electrotherapy (electric electrostimulation, ultrasound)~* Behavioral therapy
Study NCT02633007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVT-301 (levodopa inhalation powder)
Description: Capsules containing l-dopa, designed to deliver ldopa to the lung using the CVT-301 inhaler. CVT-301 will be administered 3 times, 4 hours apart, and 1 hour following the administration of carbidopa.
Study NCT02633007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa
Description: Administered orally according to the carbidopa dosing schedule.
Study NCT02633007 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo of CVT-301 is administered in the same way as the investigational product, except that it does not contain l-dopa.
Study NCT01878357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine
Description: Treatment will be given to all malaria-positive individuals on microscopic examination. The dosage will be calculated based on body weight. The drug that will be given is 3-day dihydroartemisinin-piperaquine (DHP) treatment. The drug will be given by health care personnel at their houses assisted by health care volunteers of the integrated health post (Posyandu cadre).
Study NCT01878357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: primaquine
Description: One day primaquine (PQ) treatment will be given for P. falciparum infected subjects. For patients who are infected by P. vivax and P. ovale,PQ will be given for 14 days
Study NCT04451109 — intervention group
Intervention type: DEVICE
Intervention: Dilapan-S
Description: Application of Dilapan-S and all other procedures regarding cervical ripening and induction of labor will be carried out as per the hospital's standard practice.
Study NCT03993288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrum Lek® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Lek d.d., Slovenia)
Description: Participants received Ferrum Lek® 2 tablets daily (200 mg) for 12 weeks
Study NCT03993288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MALTOFER® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Vifor S.A., Switzerland)
Description: Participants received MALTOFER® 2 tablets daily (200 mg) for 12 weeks
Study NCT04141670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S48168
Description: A novel oral small molecule which is designed to repair leaky RYR1 channels
Study NCT03494673 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: BOLD MRI
Description: 1. Prospective End-tidal targeting RespirAct device(A specially designed gas blender and sequential rebreathing circuit) will be used to implement the gas targeting method which involves precise elevations in End-tidal PCO2 while maintaining a fixed End-tidal PO2~2. BOLD MR images will be obtained by using a T2\*-weighted two-dimensional gradient-echo sequence with echoplanar readout.
Study NCT01523301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Transdermal Patch~Content:~2 mg /24 h (10 cm\^2), 4 mg /24 h (20 cm\^2), 6 mg /24 h (30 cm\^2), 8 mg /24 h (40 cm\^2)~* For early-stage Parkinson's disease, Subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 2 mg/24 h to 8 mg/24 h) for a maximum 4-week Titration Period, then 8 week Maintenance period~* For advanced-stage Parkinson's disease, Subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 4 mg/24 h to 16 mg/24 h) for a maximum 7-week Titration Period, then 8 week Maintenance period
Study NCT01523301 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Transdermal Patch~Size:~10 cm\^2, 20 cm\^2, 30 cm\^2, 40 cm\^2~Subjects randomized to placebo received matching placebo patches
Study NCT00728988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 80mg 12 hours pre-Percutaneous Coronary Intervention (PCI), 40mg 2 hours pre-PCI and 40mg daily after PCI for 30 days.
Study NCT00728988 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin
Description: 40mg daily after PCI for 30 days.
Study NCT01947257 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: the measure TRVMAX
Description: by transthoracic echocardiography
Study NCT01947257 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: the measure of the pulmonary artery
Description: by transesophageal ultrasound
Study NCT01947257 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: the direct measure of the pulmonary pressures
Description: by right catheterization
Study NCT01029769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine or amisulpride
Description: Oral olanzapine 5mg to 20mg/d OR oral amisulpride 200mg to 800mg/d; both preferably once daily, both encapsulated for blinding
Study NCT04038255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicoderm C-Q Transdermal Product
Description: 6 weeks of nicotine replacement therapy patches
Study NCT01921608 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrePex™ device
Description: PrePex™ device for adult male circumcision programs. The PrePex™ device is designed to enable conducting male circumcision procedure that is bloodless with no anesthesia and no sutures.
Study NCT00968747 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Participants will fast for 72 hours and may consume only water and vitamins.
Study NCT00968747 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Participants will follow a low-calorie diet until they lose 3-5% of their body weight.
Study NCT00968747 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oral carbohydrate challenge
Description: Participants will fast for 16 hours and then drink a beverage containing glucose, fructose or a mixture of both
Study NCT04038255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicoderm C-Q Transdermal Product
Description: 6 weeks of nicotine replacement therapy patches
Study NCT04038255 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Orientation session
Description: This session will occur 2 weeks before quit date. It will be moderated by a certified instructor in MT, and will last approximately 90 min. During the session, participants will learn the purpose, format, and procedures of the study, provide electronic informed consent which will be audio-recorded with their permission, and complete the baseline assessment.
Study NCT04038255 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Craving-to-Quit app
Description: The app is comprised of 22 modules for 22 days, 5-15 minutes each, designed to teach MT using audio, video, and animation. The app also includes other features such as social support (quit friend sign-ups, the tip of the week), activity feed (to track interaction with the app), and my morning stats (to track smoking).
Study NCT01350362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tideglusib
Description: 1000 mg of tideglusib as a powder for oral suspension once daily in an overnight fasted state for 26 weeks/extension.
Study NCT01350362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tideglusib
Description: 1000 mg of tideglusib as a powder for oral suspension once every other day in an overnight fasted state for 26 weeks/extension
Study NCT01350362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tideglusib
Description: 500 mg of tideglusib as a powder for oral suspension once daily in an overnight fasted state for 26 weeks/extension.
Study NCT01350362 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Powder for oral suspension administered once daily in an overnight fasted state for 26 weeks/extension.
Study NCT03196583 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Velo-Lingual Bite (BVL)
Description: The administration of the device will proceed according to both the essential requirements of the European directives concerning medical devices (Annex I and X of directive 93/42/EEC) and the clinical practice standards and guidelines provided by the AASM and AASDM. These include the obtainment of alginate impression of both jaws and an interocclusal record, with the mandible at 50% of its maximal protrusive position. Since no single standard titration protocol is available, progressive mandibular advancement will be conducted according to the best available medical standard.
Study NCT00979654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sifalimumab
Description: All participants will receive intravenous (IV) sifalimumab as fixed dose of 500 mg every 2 weeks (Q2W) on Day 1, Week 2, and Week 4, then every 4 weeks (Q4W) thereafter for a total of 156 weeks. The initial fixed dose of 500 mg is increased to 600 mg with subsequent protocol amendment.
Study NCT01532934 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational enhancement therapy
Description: Four 45-minute MET sessions